Updated: May 3, 2020
Remdesivir an experimental drug developed by Gilead as a treatment for Ebola virus disease. (used in trials in Liberia known as PREVAIL 4). Remdesivir is no longer being administered to patients with Ebola virus..
Remdesivir is FDA approved for SEVERE Covid-19 pneumonia in hospitalized patients. Dose: 200 mg IV on day 1 then 100mg IV once daily for up to 10 days.
“FDA’s emergency authorization of remdesivir, two days after the National Institutes of Health’s clinical trial showed promising results, is a significant step forward in battling COVID-19 and another example of the Trump Administration moving as quickly as possible to use science to save lives,” said HHS Secretary Alex Azar